Cargando…
Neuropsychiatric Symptoms of Multiple Sclerosis: State of the Art
Multiple Sclerosis (MS) is a chronic disabling neuroinflammatory disease. Psychiatric manifestations have a high prevalence in MS patients and may worsen the illness progression and the patients’ quality of life (QoL). Depression is a highly prevalent condition in MS patients, associated with poorer...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Neuropsychiatric Association
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933139/ https://www.ncbi.nlm.nih.gov/pubmed/31805761 http://dx.doi.org/10.30773/pi.2019.0106 |
_version_ | 1783483145026273280 |
---|---|
author | Silveira, Celeste Guedes, Renato Maia, Diana Curral, Rosário Coelho, Rui |
author_facet | Silveira, Celeste Guedes, Renato Maia, Diana Curral, Rosário Coelho, Rui |
author_sort | Silveira, Celeste |
collection | PubMed |
description | Multiple Sclerosis (MS) is a chronic disabling neuroinflammatory disease. Psychiatric manifestations have a high prevalence in MS patients and may worsen the illness progression and the patients’ quality of life (QoL). Depression is a highly prevalent condition in MS patients, associated with poorer adherence to treatment, decreased functional status and QoL, and increased suicide risk. Diagnosis and treatment of this disorder is challenging because of symptom overlap. Other prevalent psychiatric comorbidities are anxiety disorders, bipolar disorder, psychotic disorders, substance misuse and personality disorders. As the illness progresses, personality changes can happen, as well as affect abnormalities. Cognitive changes occur frequently in MS patients, and affect features like processing speed, attention, learning, memory, visual spatial capabilities, and some language deficits. Disease-modifying treatments may reduce cognitive impairment because of their container action on the brain’s lesion burden. Other QoL determinants such as fatigue, pain, sexual dysfunction, exercise, resilience and social support should be taken into account, in order to promote the individuals’ well-being. Further studies are needed in order to elucidate the effectiveness of pharmacotherapy and more neuroimaging studies are required to clarify the relationship between structural changes and psychiatric comorbidities. |
format | Online Article Text |
id | pubmed-6933139 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Korean Neuropsychiatric Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-69331392020-01-02 Neuropsychiatric Symptoms of Multiple Sclerosis: State of the Art Silveira, Celeste Guedes, Renato Maia, Diana Curral, Rosário Coelho, Rui Psychiatry Investig Review Article Multiple Sclerosis (MS) is a chronic disabling neuroinflammatory disease. Psychiatric manifestations have a high prevalence in MS patients and may worsen the illness progression and the patients’ quality of life (QoL). Depression is a highly prevalent condition in MS patients, associated with poorer adherence to treatment, decreased functional status and QoL, and increased suicide risk. Diagnosis and treatment of this disorder is challenging because of symptom overlap. Other prevalent psychiatric comorbidities are anxiety disorders, bipolar disorder, psychotic disorders, substance misuse and personality disorders. As the illness progresses, personality changes can happen, as well as affect abnormalities. Cognitive changes occur frequently in MS patients, and affect features like processing speed, attention, learning, memory, visual spatial capabilities, and some language deficits. Disease-modifying treatments may reduce cognitive impairment because of their container action on the brain’s lesion burden. Other QoL determinants such as fatigue, pain, sexual dysfunction, exercise, resilience and social support should be taken into account, in order to promote the individuals’ well-being. Further studies are needed in order to elucidate the effectiveness of pharmacotherapy and more neuroimaging studies are required to clarify the relationship between structural changes and psychiatric comorbidities. Korean Neuropsychiatric Association 2019-12 2019-12-09 /pmc/articles/PMC6933139/ /pubmed/31805761 http://dx.doi.org/10.30773/pi.2019.0106 Text en Copyright © 2019 Korean Neuropsychiatric Association This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Silveira, Celeste Guedes, Renato Maia, Diana Curral, Rosário Coelho, Rui Neuropsychiatric Symptoms of Multiple Sclerosis: State of the Art |
title | Neuropsychiatric Symptoms of Multiple Sclerosis: State of the Art |
title_full | Neuropsychiatric Symptoms of Multiple Sclerosis: State of the Art |
title_fullStr | Neuropsychiatric Symptoms of Multiple Sclerosis: State of the Art |
title_full_unstemmed | Neuropsychiatric Symptoms of Multiple Sclerosis: State of the Art |
title_short | Neuropsychiatric Symptoms of Multiple Sclerosis: State of the Art |
title_sort | neuropsychiatric symptoms of multiple sclerosis: state of the art |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933139/ https://www.ncbi.nlm.nih.gov/pubmed/31805761 http://dx.doi.org/10.30773/pi.2019.0106 |
work_keys_str_mv | AT silveiraceleste neuropsychiatricsymptomsofmultiplesclerosisstateoftheart AT guedesrenato neuropsychiatricsymptomsofmultiplesclerosisstateoftheart AT maiadiana neuropsychiatricsymptomsofmultiplesclerosisstateoftheart AT curralrosario neuropsychiatricsymptomsofmultiplesclerosisstateoftheart AT coelhorui neuropsychiatricsymptomsofmultiplesclerosisstateoftheart |